Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TG Therapeutics Inc (TGTX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance

TG Therapeutics IncTrade
Vanguard Tax Managed Fund FTSE Developed Markets ETFTrade

Price performance (Past 24H)

Key statistics

TG Therapeutics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? TG Therapeutics Inc trades at $54.06 (market cap $8.26B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.48. Which is the better fit depends on your goals.

TGTXVEA
Market Cap
$8.26B
Sector
Health
52-Week High
$59.06$72.39
52-Week Low
$26.39$56.02
Enterprise Value
$8.50B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX

About Vanguard Tax Managed Fund FTSE Developed Markets ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VEA